Rtw Investments Adds $14M in Castle Biosciences, Inc. ($CSTL)
RTW Investments increased its CSTL holdings by 643,098 shares, now holding 2.76 million shares.
Key Points
- RTW Investments increased its CSTL stake by 643,098 shares, now holding 2.76 million shares valued at $57.97 million.
- CSTL shares traded around $21.02 with a recent analyst consensus maintaining a 'buy' rating and targets up to $52.
- Insiders including Derek Maetzold and Ellen Goldberg engaged in buying and selling activities in late May and early June.
RTW Investments has significantly increased its position in CSTL, adding 643,098 shares in its latest move. This brings its total holdings to 2,758,335 shares, reflecting a 30% increase. As of the latest SEC filing, these shares are valued at approximately $57.97 million.
What Changed in RTW Investments' CSTL Position
RTW Investments' recent filing shows a substantial boost in its CSTL holdings. The firm previously owned 2,115,237 shares and has now increased this by 643,098 shares, resulting in a new total of 2,758,335 shares. This change represents a 30.4% increase in their stake, with the value of the holdings standing at $57.97 million.
Other Institutional Activity in CSTL
In addition to RTW Investments, other institutional investors have also adjusted their positions in CSTL. BlackRock, Inc. reduced its holdings by 122,300 shares, now holding 2,982,946 shares valued at approximately $73.23 million. Principal Financial Group Inc trimmed its position by 37,767 shares, ending with 1,769,877 shares worth about $43.45 million. Portolan Capital Management, LLC cut its stake by 379,180 shares, now holding 1,350,283 shares valued at $33.15 million. Meanwhile, Vanguard Capital Management LLC established a new position with 1,177,522 shares valued at $28.91 million.
CSTL Stock Snapshot
Shares of CSTL are trading around $21.02. The stock has seen varied institutional interest, as reflected in the recent movements by major funds. The current market sentiment is supported by analyst ratings, which remain positive.
Insider Buying and Selling at Castle Biosciences, Inc.
Recent insider activities at CSTL include several transactions. On June 1, 2026, Derek Maetzold, the President and CEO, sold 6,214 shares and also bought 6,214 shares at an average price of $2.39. Additionally, he sold 9,836 shares at $20.86 under a planned sale. On May 28, 2026, insiders Ellen Goldberg, Rodney Cotton, and Kim Caple each bought 11,766 shares.
Analysts Set New Price Targets
Analyst firms have maintained positive ratings on CSTL. On May 13, 2026, BTIG maintained its 'buy' rating with a $40 price target. Earlier, on May 7, 2026, Baird reiterated its 'buy' rating with a target of $43. Canaccord Genuity also maintained a 'buy' rating with a $40 target on April 20, 2026. The consensus remains bullish, with a target mean price reflecting strong confidence among analysts.
About CSTL
CSTL operates in the healthcare sector, focusing on providing advanced diagnostic and prognostic tests for various medical conditions. The company is headquartered in the United States and continues to expand its portfolio of medical testing solutions.
Bottom Line
RTW Investments' increased stake in CSTL highlights its confidence in the company's potential. As the 13F filings are backward-looking, this move provides insight into RTW's strategy as of the reporting period. With active insider trading and positive analyst ratings, CSTL remains a stock to watch in the healthcare sector.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.